Related references
Note: Only part of the references are listed.Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients With Relapsed or Refractory Non-Hodgkin's or Hodgkin's Lymphoma
D. R. Mould et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
Antonius A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Quercetin pharmacokinetics in humans
Young J. Moon et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2008)
Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9
Zheng Jiao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma
Lokesh Jain et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
Radojka M. Savic et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
K. Mross et al.
EUROPEAN JOURNAL OF CANCER (2007)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
C Lathia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer
TM Bosch et al.
CLINICAL PHARMACOKINETICS (2006)
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
ER Lepper et al.
CLINICAL CANCER RESEARCH (2005)
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
M Moore et al.
ANNALS OF ONCOLOGY (2005)
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
JW Clark et al.
CLINICAL CANCER RESEARCH (2005)
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
A Awada et al.
BRITISH JOURNAL OF CANCER (2005)
Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo
P He et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Population pharmacokinetics of APOMINE™:: A meta-analysis in cancer patients and healthy males
PL Bonate et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
L Paoluzzi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver
H Girard et al.
PHARMACOGENETICS (2004)
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs
L Villeneuve et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Share Paper
